• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Perrigo Company plc

    5/7/25 5:23:16 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRGO alert in real time by email
    S-8 1 d841944ds8.htm S-8 S-8

    As Filed with the Securities and Exchange Commission on May 7, 2025

    Registration Statement No. 333-   

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    PERRIGO COMPANY PLC

    (Exact name of registrant as specified in its charter)

     

     

     

    Ireland   Not Applicable

    (State or other jurisdiction of

    incorporation or organization)

      (IRS Employer
    Identification No.)

    The Sharp Building, Hogan Place

    Dublin 2, Ireland

    Telephone: +353 1 7094000

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive office)

     

     

    PERRIGO COMPANY PLC 2019 LONG-TERM INCENTIVE PLAN

    (Full Title of the Plan)

     

     

    Charles M. Atkinson

    Executive Vice President, General Counsel and Company Secretary

    Perrigo Company plc

    515 Eastern Avenue

    Allegan, Michigan 49010

    Telephone: (269) 686-1941

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copies to:

    Alan J. Fishman

    Sullivan & Cromwell LLP

    125 Broad St

    New York, New York 10004

    (212) 558-4000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐ (Do not check if a smaller reporting company)    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    EXPLANATORY NOTE

    This Registration Statement on Form S-8 (the “Registration Statement”) relates to the registration of ordinary shares, nominal value €0.001 per share (the “Ordinary Shares”), of Perrigo Company plc (the “Company” or “Registrant”) to be offered under the Perrigo Company plc 2019 Long-Term Incentive Plan (the “2019 Plan”). The 2019 Plan was adopted as an amendment and restatement of the 2013 Long-Term Incentive Plan (the “2013 Plan”), which was adopted as an amendment and restatement of the 2008 Long-Term Incentive Plan (the “2008 Plan”), which was adopted as an amendment and restatement of the 2003 Long-Term Incentive Plan (the “2003 Plan”). The Company has earlier filed registration statements on Form S-8 (File No. 333-277416 and 333-270089 and 333-261074) relating to the 2019 Plan as well as a Form S-8 (File No. 333-192946) relating to the 2013 Plan, the 2008 Plan, the 2003 Plan (the “Earlier Registration Statements”). Except as modified or superseded herein, the contents of the Earlier Registration Statements are incorporated herein by reference. This Registration Statement is being filed by the Company pursuant to General Instruction E for Form S-8 to register the issuance of an additional 1,412,770 Ordinary Shares that have become available for delivery with respect to awards under the 2019 Plan pursuant to the share counting, share recycling and other terms and conditions of the 2019 Plan.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 8.

    Exhibits.

    The following documents are filed or incorporated by reference as part of this Registration Statement.

     

    Exhibit
    Number

      

    Description of Exhibit

    4.1    Certificate of Incorporation of Perrigo Company plc (formerly known as Perrigo Company Limited) (incorporated by reference from Exhibit 4.1 to the Company’s Registration Statement on Form S-8 filed December 19, 2013) (File No. 333-192946).
    4.2    Memorandum and Articles of Association of Perrigo Company plc, as amended and restated (incorporated by reference from Exhibit 3.2 to the Company’s Quarterly Report on Form 10-Q filed on May 7, 2025) (File No. 001-36353).
    4.3    Perrigo Company plc 2019 Long-Term Incentive Plan (incorporated by reference from Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on April 30, 2019) (File No. 001-36353).
    4.4    Amendment No. 1 to Perrigo Company plc 2019 Long Term Incentive Plan (incorporated by reference from Exhibit  A to the Company’s Definitive Proxy Statement filed on March 24, 2022) (File No. 001-36353).
    4.5    Amendment No. 2 to the Perrigo Company plc 2019 Long-Term Incentive Plan, dated August  2, 2023 (incorporated by Reference from Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed on November 7, 2023) (File No. 001-36353).
    4.6    Amendment No. 3 to the Perrigo Company plc 2019 Long-Term Incentive Plan, dated November  1, 2023 (incorporated by Reference from Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q filed on November 7, 2023) (File No. 001-36353).
    5.1*    Opinion of A&L Goodbody

     

    1


    23.1*    Consent of Ernst & Young LLP, independent registered public accounting firm for Perrigo Company
    23.3*    Consent of A&L Goodbody (included in Exhibit 5.1)
    24.1*    Powers of Attorney (included as part of the signature page hereto)
    107*    Filing Fee Table

     

    *

    Filed herewith.

     

    2


    SIGNATURES AND POWER OF ATTORNEY

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Dublin, Ireland, on May 7, 2025.

     

    PERRIGO COMPANY PLC
    By:   /s/ Charles M. Atkinson
      Charles M. Atkinson
      Executive Vice President, General Counsel and Secretary

    POWER OF ATTORNEY

    Each person whose signature appears below constitutes and appoints Patrick Lockwood-Taylor, Eduardo Bezerra and Charles Atkinson, and each of them, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Registration Statement, and to file the same with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated on May 7, 2025.

     

    Signature

      

    Title

    /s/ Patrick Lockwood-Taylor

    Patrick Lockwood-Taylor

      

    Chief Executive Officer and President

    (Principal Executive Officer) and Director

    /s/ Eduardo Bezerra

    Eduardo Bezerra

      

    Chief Financial Officer and Executive Vice President

    (Principal Accounting and Financial Officer)

    /s/ Orlando D. Ashford

    Orlando D. Ashford

       Director, Chairman of the Board

    /s/ Bradley A. Alford

    Bradley A. Alford

       Director

    /s/ Julia Brown

    Julia Brown

       Director

    /s/ Kevin Egan

    Kevin Egan

       Director

    /s/ Adriana Karaboutis

    Adriana Karaboutis

       Director

     

    3


    /s/ Jeffrey B. Kindler

    Jeffrey B. Kindler

       Director

    /s/ Albert A. Manzone

    Albert A. Manzone

       Director

    /s/ Donal O’Connor

    Donal O’Connor

       Director

    /s/ Geoffrey M. Parker

    Geoffrey M. Parker

       Director

    /s/ Jonas Samuelson

    Jonas Samuelson

       Director

     

    4

    Get the next $PRGO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRGO

    DatePrice TargetRatingAnalyst
    11/6/2025$20.00Overweight → Neutral
    Analyst
    1/14/2025Buy → Hold
    Argus
    1/6/2025$34.00 → $27.00Overweight → Neutral
    Piper Sandler
    9/24/2024$50.00 → $30.00Hold
    Jefferies
    11/17/2023$37.00Overweight
    Piper Sandler
    3/7/2023$49.00Buy
    Canaccord Genuity
    9/14/2022$46.00Hold → Buy
    Argus
    9/6/2022$48.00 → $54.00Equal Weight → Overweight
    Wells Fargo
    More analyst ratings

    $PRGO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CRH, Carvana and Comfort Systems USA Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Dec. 5, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 22, to coincide with the quarterly rebalance. The changes ensure that each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space.  Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector Dec 22, 2025  S&P 500 Addition CRH CRH Mat

    12/5/25 5:49:00 PM ET
    $ASIX
    $BAH
    $BWA
    Major Chemicals
    Industrials
    Professional Services
    Consumer Discretionary

    Perrigo to Attend Morgan Stanley Global Consumer & Retail Conference

    DUBLIN, Nov. 18, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of consumer health products, today announced that President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to participate in one-on-one investor meetings at the Morgan Stanley Global Consumer & Retail Conference on Tuesday, December 2nd, 2025. About Perrigo   Perrigo Company plc is a leading pure-play consumer health company with over a century of experience in providing high-quality health and wellness solutions to consumers primarily in North America and Europe. A

    11/18/25 8:00:00 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perrigo Reports Third Quarter 2025 Financial Results From Continuing Operations

    Amid Soft Market Consumption Trends, Achieved Q3 2025 Dollar, Unit and Volume Share(1) Gains in 5 of 7 Over-The-Counter ("OTC") Store Brand Categories and Dollar Share Gains in Key Brands Despite Marketplace Challenges, Delivered Meaningful YTD 2025 EPS Growth(2) with Gross and Operating Margin Expansion  Initiates Strategic Review of Infant Formula Business (Announced in Separate Press Release); Continues Strategic Review of Oral Care Business; On-Track to Close Previously Announced Sale of Dermacosmetics Business in Q1'26 Updates Full Year 2025 Outlook Due Primarily to Infant Formula Industry Dynamics and Soft OTC Market Consumption Trends DUBLIN, Nov. 5, 2025 /PRNewswire/ --

    11/5/25 6:35:00 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Perrigo downgraded by Analyst with a new price target

    Analyst downgraded Perrigo from Overweight to Neutral and set a new price target of $20.00

    11/6/25 8:47:26 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perrigo downgraded by Argus

    Argus downgraded Perrigo from Buy to Hold

    1/14/25 8:38:48 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perrigo downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Perrigo from Overweight to Neutral and set a new price target of $27.00 from $34.00 previously

    1/6/25 8:24:36 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Perrigo Company plc

    SCHEDULE 13G/A - PERRIGO Co plc (0001585364) (Subject)

    11/14/25 12:19:22 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Perrigo Company plc

    10-Q - PERRIGO Co plc (0001585364) (Filer)

    11/5/25 3:20:40 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perrigo Company plc filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - PERRIGO Co plc (0001585364) (Filer)

    11/5/25 6:44:58 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Parker Geoffrey M. bought $106,350 worth of Ordinary Shares (7,500 units at $14.18) (SEC Form 4)

    4 - PERRIGO Co plc (0001585364) (Issuer)

    11/14/25 10:45:37 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP and CSO Lennox Abigail bought $28,125 worth of Ordinary Shares (1,255 units at $22.41) (SEC Form 4)

    4 - PERRIGO Co plc (0001585364) (Issuer)

    9/10/25 4:19:48 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, General Counsel & Sec. Atkinson Charles bought $23,200 worth of Ordinary Shares (1,000 units at $23.20) (SEC Form 4)

    4 - PERRIGO Co plc (0001585364) (Issuer)

    9/9/25 3:47:36 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Parker Geoffrey M. bought $106,350 worth of Ordinary Shares (7,500 units at $14.18) (SEC Form 4)

    4 - PERRIGO Co plc (0001585364) (Issuer)

    11/14/25 10:45:37 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by EVP, Supply, Ops, Strategy Winterman Matthew John

    4 - PERRIGO Co plc (0001585364) (Issuer)

    9/16/25 4:06:34 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Parker Geoffrey M.

    4 - PERRIGO Co plc (0001585364) (Issuer)

    9/16/25 12:16:53 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 13, 2023 - FDA Approves First Nonprescription Daily Oral Contraceptive

    For Immediate Release: July 13, 2023 Today, the U.S. Food and Drug Administration approved Opill (norgestrel) tablet for nonprescription use to prevent pregnancy— the first daily oral contraceptive approved for use in the U.S. without a prescription. Approval of this progestin-only oral contraceptive pill provides an option for consumers to purchase oral contraceptive medicine without a prescription at drug stor

    7/13/23 8:32:15 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    Leadership Updates

    Live Leadership Updates

    View All

    CRH, Carvana and Comfort Systems USA Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Dec. 5, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 22, to coincide with the quarterly rebalance. The changes ensure that each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space.  Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector Dec 22, 2025  S&P 500 Addition CRH CRH Mat

    12/5/25 5:49:00 PM ET
    $ASIX
    $BAH
    $BWA
    Major Chemicals
    Industrials
    Professional Services
    Consumer Discretionary

    Perrigo Announces Global Operations and Supply Chain Leadership Transition

    Ron Janish, EVP Global Operations and Supply Chain, to Retire Industry Veteran, Matt Winterman, Appointed EVP Product Supply, Operations Strategy & Transformation Officer DUBLIN, June 4, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced the appointment of Matt Winterman as Executive Vice President, Product Supply, Operations Strategy and Transformation Officer, effective June 23, 2025. Mr. Winterman succeeds Ron Janish, who will retire from the Company on September 30, 2025, following a distinguished career at Perrigo spanning more than two decades. Both executives will closely work together to ensure a smooth tran

    6/4/25 8:30:00 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perrigo Expands its Scientific Office; Appoints Abbie Lennox as Executive Vice President and Chief Scientific Officer

    Expanded Scientific Office Unifies Scientific-Focused Teams, Facilitating Seamless Collaboration Across Product Portfolio Lennox Most Recently Led Regulatory, Medical Affairs, Safety and Quality Teams, Plus Drove Product Innovation, at Bayer Consumer Health Previous Chief Scientific Officer, Alison Ives, to Lead Newly Formed Disruptive Growth Team DUBLIN, Jan. 6, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced the expansion of its Chief Scientific Office by uniting and integrating all global quality, pharmacovigilance, patient safety, regulatory affairs and innovation teams, enhancing organizational agility and s

    1/6/25 8:00:00 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    Financials

    Live finance-specific insights

    View All

    Perrigo Reports Third Quarter 2025 Financial Results From Continuing Operations

    Amid Soft Market Consumption Trends, Achieved Q3 2025 Dollar, Unit and Volume Share(1) Gains in 5 of 7 Over-The-Counter ("OTC") Store Brand Categories and Dollar Share Gains in Key Brands Despite Marketplace Challenges, Delivered Meaningful YTD 2025 EPS Growth(2) with Gross and Operating Margin Expansion  Initiates Strategic Review of Infant Formula Business (Announced in Separate Press Release); Continues Strategic Review of Oral Care Business; On-Track to Close Previously Announced Sale of Dermacosmetics Business in Q1'26 Updates Full Year 2025 Outlook Due Primarily to Infant Formula Industry Dynamics and Soft OTC Market Consumption Trends DUBLIN, Nov. 5, 2025 /PRNewswire/ --

    11/5/25 6:35:00 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perrigo to Conduct Strategic Review of its Infant Formula Business

    DUBLIN, Nov. 5, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO) ("Perrigo" or "the Company"), a leading provider of consumer health products, today announced that it is initiating a strategic review of its infant formula business. The review will assess a full range of alternatives. This review is aligned with Perrigo's 'Three-S' (Stabilize, Streamline, Strengthen) plan and reflects the Company's commitment to disciplined capital allocation and supporting improved return on invested capital and total shareholder return. It will focus on a combination of accelerating cash flows and reassessing the Company's previously announced investment in this business of $240 million, while optimizin

    11/5/25 6:30:00 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perrigo Announces Quarterly Dividend

    DUBLIN, Oct. 29, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of consumer health products, today announced that its Board of Directors declared a quarterly dividend of $0.290 per share, payable on December 16, 2025, to shareholders of record on November 28, 2025. About Perrigo Perrigo Company plc is a leading pure-play consumer health company with over a century of experience in providing high-quality health and wellness solutions to consumers primarily in North America and Europe. As a pioneer in the over-the-counter (OTC) self-care market,

    10/29/25 11:57:00 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRGO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Perrigo Company plc

    SC 13G - PERRIGO Co plc (0001585364) (Subject)

    10/31/24 11:55:03 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Perrigo Company plc

    SC 13G - PERRIGO Co plc (0001585364) (Subject)

    2/13/24 1:05:29 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Perrigo Company plc (Amendment)

    SC 13G/A - PERRIGO Co plc (0001585364) (Subject)

    1/24/24 2:27:16 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care